IRCT20200105046010N17尚未招募未知
Pharmacokinetic assessments of RIFANA® tablet with brand drugs (CUMADIN® 5mg - Bristol-Myers Squibb)
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
已完成
不适用
Bioavailability of the fixed dose formulation Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and the World Health Organization (WHO) recommended first line antiretroviral drugs zidovudine, lamivudine, efavirenz administered to new Tuberculosis (TB) patients at different levels of immunosuppressioISRCTN83323477World Health Organization (WHO) (Switzerland)120
尚未招募
不适用
Study of Ranolazine table In-Vivo Bioequivalence in healthy volunteersIn this study, the disease is not examined. Subject bioequivalence test and reference tablets Ranolase studied..IRCT20200105046010N13Arena life science24
进行中（未招募）
不适用
Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir TPV/r 500 mg/200 mg BID IN a racially and Gender diverse HIV-positive treatment experienced population with a pilot evaluation of therapeutic drug monitoring TDM . The SPRING study is an open-label, multicenter, multinational trial with randomisation to standard of care SOC or TDM TPV/r therapy - SPRINGRacially diverse HIV-positive population of females and males who are three-class NRTI, NNRTI, and PI experienced with a minimum of 3-months duration for each class and have documented resistance to more than one PI.MedDRA version: 9.1Level: HLTClassification code 10052740Term: Acquired immunodeficiency syndromesEUCTR2005-005264-86-ITBOEHRINGER ING.800
进行中（未招募）
不适用
Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a pilot evaluation of therapeutic drug monitoring (TDM). The SPRING study is an open-label, multicenter, multinational trial with randomisation to standard of care (SOC) or TDM TPV/r therapy - SPRING studyEUCTR2005-005264-86-DEBoehringer Ingelheim Pharma GmbH & Co. KG400
进行中（未招募）
1 期
Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, parallel group, multicenter studyEUCTR2014-003055-60-ATMedical University of Vienna90